Filter posts

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. …

Jim Greenwood on the Road: Opening Bell at NASDAQ

Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ …

The Value of Innovation to Save and Transform Lives

Patients have greater hope for cures to today’s most complex and challenging diseases thanks to …

When The Deck is Stacked Against Innovators, Everyone Loses

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the …

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Biosimilars raise novel and complex questions of science and law that require updated legal and …

Attacks on Venture Philanthropy Miss Mark Badly

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy …

Wall Street Journal Highlights Promising Gene Therapy Advances

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American …

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling …

Gates to contribute $50M for Ebola response

Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 …

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of …